Saintmed Public Company Limited

As of September 30, 2024, Saintmed Public Company Limited has 207.70M shares outstanding.

As of September 30, 2024, Saintmed Public Company Limited trades at a trailing price-to-earnings ratio of 15.75. The price-to-sales ratio is 1.05, and the price-to-book ratio stands at 1.81.

As of September 30, 2024, Saintmed Public Company Limited trades at an EV/EBITDA multiple of 7.14 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.48 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses.

As of September 30, 2024, Saintmed Public Company Limited maintains a current ratio of 2.95, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 23.16, indicating elevated leverage, while an interest coverage ratio of 19.08 demonstrates strong ability to service its debt obligations.

Over the twelve months ended September 30, 2024, Saintmed Public Company Limited posted a return on equity (ROE) of 10.21, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.50 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.55, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.97, useful for judging operating efficiency across full business cycles. Inventory turnover of 1.72 indicates how many times Saintmed Public Company Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended September 30, 2024. That works out to an effective tax rate of 20.94, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

Over the twelve months ended September 30, 2024, Saintmed Public Company Limited posted a gross margin of 36.17, reflecting its pricing power and cost economics. The operating margin of 8.66 and net profit margin of 6.64 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2024. The dividend payout ratio of 118.85 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -4.03: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 3.97, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Saintmed Public Company Limited shareholders.

Saintmed Public Company Limited's most recent stock split took place on March 15, 2022 with a 20:21 split ratio.

As of September 30, 2024, Saintmed Public Company Limited has an Altman Z-Score of 3.14, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.